May 1, 1985Clinical Pharmacology & Therapeutics
Propranolol antagonism of phenylpropanolamine-induced hypertension
Key result
Propranolol pretreatment reduces phenylpropanolamine-induced SBP increases by ~61% by reversing cardiac output effects.
Why the study?
Phenylpropanolamine overdose can cause severe hypertension, and the efficacy and safety of propranolol in treating PPA-induced hypertension were studied.
Does propranolol reduce blood pressure in subjects with phenylpropanolamine-induced hypertension?
Population
Subjects receiving phenylpropanolamine (PPA)
Comparison
Propranolol oral pretreatment or intravenous infusion vs PPA 75 mg alone
Design
Interventional study with oral and intravenous propranolol administration
Follow-up
48 hours
Authors
Discussion
Loading...
Member takes
Implication
Supports propranolol for phenylpropanolamine-induced hypertension; confirms beta-blockade utility via cardiac output reversal in RCT evidence.
Structured PICO
Does propranolol reduce blood pressure in subjects with phenylpropanolamine-induced hypertension?
P
Population
Subjects receiving phenylpropanolamine (PPA)
I
Intervention
Propranolol (either oral for 48 hours before PPA or as a rapid intravenous infusion after PPA)
C
Comparator
Phenylpropanolamine (PPA) 75 mg alone
O
Outcome
Blood pressuresurrogate
Main Result
Absolute Event Rate: 12% vs 31%
Propranolol effectively antagonizes phenylpropanolamine-induced hypertension by reversing its effect on cardiac output, despite further increasing systemic vascular resistance.
Cite This Study
Pentel et al. (1985) studied Phenylpropanolamine-induced hypertension. Propranolol vs. Phenylpropanolamine (PPA) 75 mg alone was evaluated on Systolic blood pressure increase (mm Hg). Propranolol pretreatment antagonized phenylpropanolamine-induced systolic blood pressure increases (12 mm Hg vs 31 mm Hg with PPA alone) by reversing the effect of PPA on cardiac output.